Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Versus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin + Etoposide

NCT00290953 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00290953
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00290953 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomized, Phase II-III Maintenance Study of SR48692 Versus Placebo in Patients With Extensive Stage Small Cell Lung Cancer Following a First Line Chemotherapy With Cisplatin + Etoposide
Lead sponsor
Sanofi
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2002
Completion date
March 31, 2006
Enrollment
432 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, pulmonary neoplasms, small cell lung cancer